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Abstract
Background: We conducted a pilot phase II study to evaluate the efﬁ  cacy and safety of S-1 as a ﬁ  rst-line, S-1 plus cisplatin 
as a second-line, and weekly paclitaxel as a third-line therapy for advanced gastric cancer.
Patients and methods: Between 2002 and 2005, 19 patients were enrolled in this study. Chemotherapy consisted of either 
60 mg/m
2 of S-1 for 4 weeks at 6 weeks interval, a combination of 60 mg/m
2 S-1 for 3 weeks and 60 mg/m
2 cisplatin on day 
8 at 5 weeks interval, or 60 mg/m
2 paclitaxel at day 1, 8, 15, at 4 weeks interval. The regimen was repeated until the occurrence 
of unacceptable toxicities, disease progression, or patient refusal. The primary end point was the overall survival.
Results: The response rates were 33.3%, 12.5%, and 0% after the ﬁ  rst, second, and third line chemotherapy, respectively. 
The mean overall survival time was 994 days. The median survival time could not be calculated because 12 out of 19 patients 
were still alive when the study was concluded. Regarding hematological toxicity, the major adverse effect was leukopenia, 
which reached grades 3–4 in all lines of chemotherapy investigated. In addition, regarding non-hematological toxicities, 
the major adverse effect was anorexia, which reached grade 3-4 in the second line chemotherapy, and no deaths were 
attributable to the adverse effects of the drugs.
Conclusion: This sequential therapy was an effective treatment for advanced gastric cancer with acceptable toxic side-
effects. We considered this sequential therapy to be effective because of the smooth switch to the next regimen.
Keywords: advanced gastric cancer, recurrent gastric cancer, S-1, cisplatin, paclitaxel, phase II study, ﬁ  rst-line chemotherapy, 
second-line chemotherapy, third-line chemotherapy
Introduction
Recently, several clinical trials have demonstrated the efﬁ  cacy of certain chemotherapeutic agents 
against gastric cancer (1,2). Oral ﬂ  uorouracil antitumor drugs were ﬁ  rst developed in 1971 in Japan, 
leading to the establishment of UFT (3). S-1 is a novel oral ﬂ  uorouracil antitumor drug that contains a 
combination of 3 pharmacological agents: tegafur (FT), a 5-Fluorouracil (5-FU) prodrug, 5-chloro-2, 
4-dihydroxypyridine (CDHP), which inhibits the activity of dihydropyrimidine dehydrogenase (DPD) 
and potassium oxonate (Oxo), which reduces the gastrointestinal toxicity of 5-FU. A phase II study of 
S-1 showed a 45% response rate to the drug and a median survival time of 275 days (4–10). This drug 
has gradually been accepted as the front-line chemotherapeutic agent in Japan for the treatment of 
gastric cancer cases that were unresectable, resected but not cured, or recurrent. Unfortunately, some 376
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gastric cancers do not respond to this agent. 
Therefore, in cases who S-1 therapy failed, we 
administered a second-line regimen, using or add-
ing other agents, namely, cisplatin, paclitaxel, 
docetaxel and irinotecan. When a patient admin-
istered S-1 had progressive disease, after treatment 
with cisplatin, paclitaxel, docetaxel or irinotecan 
without cross-tolerance of S-1 resulted in good 
outcome.
However, we could not find any reports 
investigating a third-line chemotherapy, 
administered drugs without cross-tolerance of prior 
chemotherapy. As such, we decided to carry out a 
single administration of S-1, and as the second-line 
chemotherapy in which cisplatin is additionally 
administered, a regimen of S-1 plus cisplatin. The 
regimen of S-1 plus cisplatin had a high response 
rate of over 70%, and it was also reported that 
side-effects at grade 3 or above accounted for less 
than 25% (11), so it was concluded that curative 
effects can be expected even after the administration 
of S-1. However, there is no evidence that clearly 
shows whether the regimen of S-1 plus cisplatin 
after S-1 failure is effective or not. Next, as the 
third-line chemotherapy, we decided to provide 
weekly paclitaxel therapy, which has no cross-
tolerance.
In this study, we evaluated S-1, S-1 plus cis-
platin, and paclitaxel as chemotherapy for advanced 
gastric cancer, by measuring the objective response 
rate, the overall survival and the safety proﬁ  le, for 
use as a ﬁ  rst-, second- and third-line chemothera-
peutic regimens.
Patients and Methods
Patient eligibility
A series of 19 patients were enrolled in this study 
between June 2002 and December 2005. To be 
eligible for inclusion, the patients had to have his-
tologically or cytologically confirmed gastric 
adenocarcinoma that was either unresectable 
(n = 3), palliatively resected (n = 10) or recurrent 
(n = 6) (Table 1). The patients had to have no prior 
chemotherapy received and were able to take S-1 
orally. Recurrent patients were allowed to be 
included if at least 3 months has elapsed after the 
last post operative adjuvant chemotherapy. S-1 was 
administered daily for two 4-week periods, sepa-
rated by a 2-week interval for the ﬁ  rst-line chemo-
therapy, after an informed consent from the patient 
has been obtained. A dose reduction was not 
allowed; however, the treatment schedule was 
changed in some cases to 5 consecutive days of 
treatment followed by 2 days of rest per week. This 
treatment schedule was repeated for 4 weeks, fol-
lowed by 2 weeks of rest. The regimen was changed 
if more than a grade 3 toxicity, progressed disease 
and escalated tumor marker were shown. However, 
if grade 3–4 toxicity was observed after the ﬁ  rst-line 
chemotherapy, then a second-line chemotherapy 
was administered after the patient recovered from 
the toxicity. If the second-line chemotherapy was 
refused by the patient who originally received S-1, 
then weekly paclitaxel was given as the second-line 
chemotherapy. The patients were also required to 
meet the following criteria: age #75 years, amenable 
to oral administration of drugs, a Karnofsky per-
formance score of 60, a life expectancy of at least 3 
months, and an adequate hematological status 
(deﬁ  ned as having a total leukocyte count  3,500/mm
3, 
neutrophil count  1,500/mm
3, platelet 
count  100,000/mm
3, serum creatinine  1.5 mg/dl, 
total serum bilirubin  1.5 mg/dl, aspartate 
aminotransferase (AST) and alanine aminotransferase 
Table 1. Characteristics of enrolled patients.
Characteristcs Number
of patients
(%)
Total number of patients 19
Age (years)
Mean ± SD (range) 61.3 ± 1.4(38-75)
Sex
Male 13 68.4
Female 6 31.6
Karnofsky performance 
status
80-100 19 100
Histological type (Japanese 
classiﬁ  cation)
Differntiated 5 26.3
Undifferentiated 14 73.7
Primary treatment
Curative gastrectomy 6 31.6
Palliative gastrectomy 10 52.6
Without gastrectomy 3 15.8
Target lesions
primary 3 15.8
peritoneal dissemination 14 73.3
lymph node metastasis 5 26.3
liver metastasis 2 10.5377
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(ALT) levels less than 2 times the upper limit of the 
normal range). Patients were excluded from the 
study if they had any other current or prior 
malignancies, active uncontrolled infections or 
other diseases, or a neurological or mental disease 
that prevented adequate comprehension of 
information. The pretreatment evaluation consisted 
of a complete history and physical examination, 
blood count, serum biochemistry, and computed 
tomography (CT) of the chest and abdomen. All 
patients gave their informed consent before the 
initiation of treatment.
Study design (Fig. 1)
First line chemotherapy
S-1 was administered orally twice daily after 
breakfast or dinner, at 80 mg/m
2/day for 4 weeks, 
followed by 2 weeks of rest. During the course of 
the treatment, the patients were evaluated the com-
plete blood count (CBC), biochemical and physical 
examinations on every 2 weeks, and for the pres-
ence of tumor markers (CEA, CA19-9, STn and 
SLX) on every 4 weeks. The treatment response 
was then evaluated by computed tomography (CT) 
on every 2 months.
Second line chemotherapy
S-1 was administered at the same dosage as the 
ﬁ  rst line chemotherapy. S-1 was administered for 
3 weeks followed by 2 weeks of rest. On day 8, S1 
was combined with cisplatin at 60 mg/m
2. The 
patients were pre-medicated with 8 mg dexa-
methasone and 10 mg azasetron hydrochrolide 
diluted in 50 ml of saline, given intravenously 30 
minutes prior to treatment. Chemotherapy was then 
administered by intravenous infusion and it con-
sisted of 60 mg/m
2 cisplatin administered over 120 
minutes. During the course of the treatment, the 
patients were evaluated CBC, biochemical and 
physical examinations on every 2–3 weeks, and on 
every 4 weeks, for tumor markers (CEA, CA19-9, 
STn and SLX). The treatment response was 
evaluated on every 2 months by CT.
Third line chemotherapy
Paclitaxel was administered at 60 mg/m
2 on day 
1, 8, and 15 of a 4-week treatment cycle. Prior to 
the paclitaxel administration, the patients were 
given 50 mg diphenhydramine orally and 20 mg 
dexamethasone intravenously with 50 ml saline 
water over 30 min, 50 mg ranitidine hydrochloride 
intravenously with 50 ml saline water over 30 min, 
10 mg azasetron hydrochrolid intravenously with 
50 ml saline water over 30 min. Paclitaxel was 
administered by intravenous infusion and it 
consisted of 60 mg/m
2 over 60 minutes.
All patients were admitted to the hospital for 
the ﬁ  rst intravenous treatment of the second and 
third line chemotherapy. The succeeding intrave-
nous treatments were performed on an out-patient 
basis.
If hematological or non-hematological toxicities 
of grade 3 or higher occurred, or if patients 
requested that the treatment be stopped.
Study evaluations
All responses were assessed by physical examina-
tion, direct visualization, examination of the upper 
gastrointestinal tract after a barium meal, gastro-
ﬁ  broscopy and CT. A tumor evaluation was carried 
out every two months, according to the World 
Health Organization criteria, and the responses 
were conﬁ  rmed by radiography within 2 weeks. 
1st line: S-1 80 mg/m2
S-1
Day 1                                          28                42 
2nd line: S-1  80 mg/m2  ,  CDDP  60 mg/m2
CDDP
S-1
Day 1        8                          21                    35
3rdline: Paclitaxel 60 mg/m2
Day 1        8        15                 28
Figure 1. Protocols of First-, Second-, and Third-line chemotherapy.
First line chemotherapy: S-1 was administered orally twice daily 
after breakfast or dinner, at 80 mg/m
2/day for 4 weeks, followed by 
2 weeks of rest.
Second line chemotherapy: S-1 was administered at the same 
dosage as the ﬁ  rst line chemotherapy. S-1 was administered for 3 
weeks followed by 2 weeks of rest. On day 8, S-1 was combined with 
cisplatin at 60 mg/m
2.
Third line chemotherapy: Paclitaxel was administered at 60 mg/m
2 
on day 1, 8, and 15 of a 4-week treatment cycle.378
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A complete response (CR) was defined as a 
remission of all diseases for a minimum of 4 weeks. 
A partial response (PR) was deﬁ  ned as a  50% 
reduction in the product of the perpendicular 
diameters of the indicator lesions, without the 
appearance of new lesions. Progressive disease 
(PD) was deﬁ  ned as an enlargement of  25% in 
an indicator lesion or the development of new 
lesions, and no change (NC) was deﬁ  ned as a 
failure to meet the criteria for either the response 
or progression. All adverse events were graded 
using the National Cancer Institute Common 
Toxicity Criteria (NCI-CTC) at each treatment 
cycle. In the event of toxicity, chemotherapy was 
postponed until the symptoms had resolved.
Survival analysis
Because the few patients had measurable lesion, 
the primary end point of this study was the overall 
survival (OS). The Kaplan-Meier method was used 
to calculate the survival rate. The difference 
between the curves was assessed using the log-rank 
test. Results with probability (p) values   = 0.05 
were considered to be statistically signiﬁ  cant. A 
statistical calculation was conducted using the Dr. 
SPSS II for Windows software program.
Results
Patient characteristics
The demographic features of the 19 patients 
enrolled in this study are shown in Table I. All 
patients were assessed for response and toxicity. 
The median patient age was 61.3 years (range: 
38–75 years); 12 patients were male (63.2%) and 
7 were female (36.8%), with all patients being in 
good general condition (Karnofsky performance 
status: 80-100). All patients had histologically 
conﬁ  rmed adenocarcinoma, with 6 differentiated, 
and 13 undifferentiated adenocarcinomas. The 
most frequently observed sites of tumors were the 
peritoneal dissemination in 14 patients, the lymph 
nodes metastasis in 5 patients, followed by the 
primary tumor site in 3 patients and liver metasta-
ses in 2 patients.
The ﬁ  rst-line was performed in 19 cases, and 
6.2 courses of administration, on average, could 
be performed (range: 0–20). The second-line was 
performed in 13 cases, with 2.8 courses on 
average performed (range: 1–7). The third-line 
was performed in 13 cases, with 3.8 courses on 
average (range: 0–14). The cases with 0 courses 
in the ﬁ  rst-line and third-line were the result of 
refusal by the patients due to side-effects as well 
as rapidly increased lesions. The fourth-line and 
subsequent treatments were performed in 8 cases. 
None of the patients underwent subsequent 
surgery.
Efﬁ  cacy
There were assessable lesions in 9 cases within the 
ﬁ  rst-line, 8 cases in the second-line, and 4 cases in 
the third-line. In the ﬁ  rst-line, 1 case of CR and 2 
cases of PR were found, and in the second-line, 
there was 1 case of PR, but in the third-line neither 
PR nor CR were found. The response rates (RR) 
were 33.3%, 12.5%, and 0% for each therapy. As 
for response regions, in CR for the ﬁ  rst-line, there 
was lymph node metastasis, and in PR, there were 
liver metastasis, peritoneal dissemination, and 
primary tumors. There was liver metastasis in PR 
for the second-line.
Survival
The mean follow-up time was 726 days with a 
range of 44 to 1461 days. The mean time to pro-
gression was 314.3 days with a range of 33 to 845 
days. The median survival time (MST) for patients 
over the whole course of their treatment was not 
calculated because 12 out of 19 patients were still 
alive. The mean survival time was 994 days 
(Fig. 2). In the non-curative resection patients 
(n = 10), the mean survival time was 1207.4 days 
and the MST was not calculated because the 8 
patients were still alive. In the non-resection 
patients (n = 3), the mean survival time was 727.7 
days, 2 patients died, and the MST was 522 days. 
In the recurrent patients (n = 6), the mean survival 
time was 644.5 days, 3 patients died, and the MST 
was 376 days. There were no signiﬁ  cant differences 
between the non-curative resection, non- resection, 
and recurrent patients (Fig. 3).
Toxicity
Regarding hematological toxicity, leucopenia, 
which is a side-effect with at least grade 3 severity, 
was most frequently found, followed by anemia. 
In the ﬁ  rst-line, 1 case of leucopenia and 1 case of 
neutropenia (10.5%) were found; in the second-
line, 3 cases of leucopenia and 2 cases of anemia 379
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(23.1%); and in the third-line, 2 cases of leucopenia 
and 1 case of anemia (23.1%). As for non-
hematological toxicity, a loss of appetite was most 
frequently found. In the first-line, 1 case of 
stomatitis, 1 case of lachrymation, and 1 case of 
numbness in limbs (10.5%); in the second-line, 1 
case of nausea, 4 cases with a loss of appetite, 2 
cases of diarrhea, 1 case of fatigue, and 1 case of 
abdominal pain (46.2%); and in the third-line, not 
a single case was found. (Table 2)
1 2                   3                  4 (year)
100
50
(%)
Figure 2. Over all Survival curve (n = 19). The mean survival time was 994.0 6 127.1 days.
100
50
(%)
1 2                          3                        4 (year)
non-curative resection patients (n = 10)
non-resection patients (n = 3)
recurrent patients (n = 6)
Figure 3. Survival curves of every primary treatments. In the non-curative resection patients (n = 10), the mean survival time was 1207.4 ± 132.1 
days and the median survival time (MST) was not calculated. In the non-resection patients (n = 3), the mean survival time was 727.7 ± 271.7 
days, and the MST was 522 days. In the recurrent patients (n = 6), the mean survival time was 644.5 ± 201.3 days and the MST was 376 days. 
There were no signiﬁ  cant differences between the non-curative resection, non- resection and recurrent patients.380
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Table 2. Adverse events, according to regimen group.
Regimen Type Grade
1 2 3 4 %3 and 4
TS1 (n = 19)
diarrhea 2 3 0 0 0
constipation 1 0 0 0 0
nausea 2 1 0 0 0
anorexia 1 5 0 0 0
vomiting 1 1 1 0 5.3
headache 2 0 0 0 0
fatigue 7 2 0 0 0
stomatitis 0 5 1 0 5.3
dizziness 1 1 0 0 0
AST,ALT 2 1 0 0 0
lachrymation 3 1 0 0 0
photophobia 3 0 1 0 5.3
dysgeusia 1 1 0 0 0
alopecia 1 0 0 0 0
pigmentation 3 1 0 0 0
nail changes 1 1 0 0 0
conjunctivitis 1 0 0 0 0
numbness of limbs 2 0 1 0 5.3
abdominal pain 1 0 0 0 0
edema 1 1 0 0 0
allergic rhinitis 1 1 0 0 0
anemia 0 1 0 0 0
leukopenia 0 1 1 0 5.3
neutropenia 0 0 1 0 5.3
TS1 + CDDP (n = 13)
diarrhea 2 0 2 0 15.4
nausea 0 0 1 0 7.7
anorexia 2 1 4 0 30.8
fatigue 2 2 1 0 0
AST,ALT 0 1 0 0 0
alopecia 1 0 0 0 0
pigmentation 2 0 0 0 0
abdominal pain 0 1 1 0 7.7
edema 0 1 0 0 0
hypotension 1 0 0 0 0
epistaxis 1 0 0 0 0
rash 1 0 0 0 0
anemia 0 1 2 0 15.4
leukopenia 0 1 3 1 30.8
neutropenia 0 0 2 0 15.4
lymphopenia 0 0 0 1 7.7
Weekly paclitaxel (n = 13)
diarrhea 2 1 0 0 0
constipation 0 1 0 0 0
(Continued)381
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Discussion
S-1 has been the most widely used anti-cancer drug 
for advanced or recurrent gastric cancer in Japan. 
S-1, a newly developed oral tegafur compound, 
contains CDHP, which transiently, but strongly, 
inhibits DPD. The presence of this enzyme in the 
formulation allows the plasma concentration of 
5-FU to be maintained at a high level for 8 h, giv-
ing a high response rate for gastric cancer. Another 
phase II study has shown a response rate to S-1 of 
45% and a median survival time of 275 days. In 
addition, S-1 treatment can be administered on an 
outpatient basis, which is a striking difference from 
other intensive chemotherapies, including regi-
mens with low-dose 5-ﬂ  uorouracil and cisplatin 
(12,13) and MTX/5FU (14). The high response 
rate thereby raises hopes that the survival rates in 
advanced or recurrent gastric cancer may thus 
increase with this treatment.
S-1 is active, even against disseminated perito-
neal metastases in gastric carcinoma patients, as 
conﬁ  rmed by Mori et al. (15) in a mouse model of 
gastric cancer with disseminated peritoneal dis-
ease. A high concentration of 5-FU has been 
detected in the intraperitoneal tumor lesions of the 
S-1 group, and prolonged survival rates were 
observed. However, the mechanism by which the 
high concentration of 5-FU were maintained in the 
peritoneal cavity is not yet known.
In more than 4,000 patients administered S-1 
for gastric cancer, 25% have been reported to 
experience grade 3 or higher toxicities, and their 
median survival rate was 8.3 months (16). We 
herein observed an occurrence of grade 3 or higher 
toxicities in 9.4%, a response rate of 38.4%, and a 
median survival rate of 343 days in the patients 
who received S-1 monotherapy for advanced or 
recurrent gastric cancer (17).
In a report comparing S-1 plus CDDP admin-
istration and the single administration of S-1, side-
effects with at least grade 3 severity were 43.5% 
and 22.5%, respectively, for each administration, 
and in combined therapy, side-effects occurred 
about twice as often as in single therapy, with 
36.8% and 25.9% of RR, respectively, which is 
obviously higher in the combined therapy. How-
ever, MST was 319 days and 322 days, respec-
tively, which indicates that the therapies did not 
contribute in any way to the extension of survival 
time (18). Therefore, when chemotherapy is started 
with S-1 alone and it is found to be ineffective, it 
is expected that adding CDDP to the therapy does 
not shorten the survival time but, instead, it main-
tains the response rate with less incidence of side-
effects. Thus, we believe that our ﬁ  rst-line and 
second-line therapies are reasonable. Similar to 
previous reports regarding side-effects with at least 
grade 3 in severity, non-hematological toxicity 
accounted for 10.5% and 46.2%, respectively, in 
S-1 and S-1 + CDDP, and hematological toxicity 
was 10.5% and 23.1%, respectively. Even when 
S-1 + CDDP was administered after S-1, side-effects 
Weekly paclitaxel (n = 13)
nausea 3 0 0 0 0
anorexia 1 0 0 0 0
fatigue 3 0 0 0 0
dizziness 0 1 0 0 0
AST,ALT 1 1 0 0 0
lachrymation 1 0 0 0 0
dysgeusia 1 0 0 0 0
alopecia 3 1 0 0 0
numbness of limbs 2 1 0 0 0
edema 0 1 0 0 0
insomnia 1 0 0 0 0
anemia 0 0 1 0 7.7
leukopenia 0 1 2 0 15.4
neutropenia 0 1 2 0 15.4
Regimen Type Grade
Table 2. Continued.382
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did not increase significantly. S-1 + CDDP 
administration was performed 2.8 times on average, 
with a median value of 2 times, which is lower than 
the median value of 4 times in the previous report 
(11). This is due to the progression of the disease 
rather than side-effects. The response rate in the 
single administration of S-1 was 33.3% as expected, 
but the response rate in S-1 + CDDP in the second-
line was 12.5%—far less than the 74% discovered 
by Koizumi et al. (11). It is believed that this is 
the reason for the decrease in the number of 
administrations of S-1 + CDDP.
We adopted this approach because paclitaxel 
used in this regimen showed no cross-resistance and 
had completely different side-effect proﬁ  le (19).
At the beginning of this therapy, weekly pacli-
taxel therapy for gastric cancer had not been estab-
lished, so we decided on a dose by referring to the 
reports for other types of cancer and tumors. In 
ovary cancers, 80 mg/m
2 is the maximum-tolerable 
dose, but it has been reported that the incidence of 
neuropathy is frequently found with 60 mg/m
2 (20). 
In breast cancers, it has been reported that Cmax 
was high at 60 mg/m
2 (21), which is recommended 
together with radiation therapy in lung cancers 
(22). From these reports, we decided to perform 
weekly paclitaxel therapy with 60 mg/m
2 as the 
next chemotherapy for S-1 + CDDP. In recent 
reports of weekly paclitaxel therapy for gastric 
cancers, the dose of paclitaxel is 80 mg/m
2, and 
we also provided weekly paclitaxel therapy as the 
second-line chemotherapy, following S-1 in pre-
treatment, with a dose of 80 mg/m
2. In this therapy, 
the RR was 0%, MST was 495 days, and 11.8% 
hematological toxicity with at least grade 3 in 
severity was recognized (23). In other reports of 
weekly paclitaxel therapy with a dose of 80 mg/m
2, 
it was indicated that the initial treatment RR was 
14.3%, MST was 221 days, side-effects with at 
least grade 3 in severity were 0%, and the median 
value of the number of times it was performed was 
2.0 (24). In addition, it was reported that the dose 
was 70 mg/m
2 in mixed cases with pretreatment 
and initial treatment, but the RR was 33%, MST 
was 160 days, hematological toxicity with at least 
grade 3 in severity was 27.2%, and the average 
number of times it was performed was 5.4 (25). In 
this therapy, the dose of paclitaxel was 60 mg/m
2, 
and after treatment with S-1 and S-1 plus CDDP, 
neither CR nor PR developed. However, non-
hematological toxicity was not found, and only 
23.1% hematological toxicity was found. The 
average number of times it was performed was 3.8, 
with a median value of 4. As the third-line, follow-
ing S-1 and S-1 plus cisplatin—protocols with a 
relatively high frequency of side-effects—a dose 
of 80 mg/m
2 may be possible, but this is unclear, 
as we do not have any relevant experiences.
Thus, in this therapy, the response rate was low, 
but survival time was excellent. Average survival 
time was about 1,000 days, and no reports with 
outcomes too good to calculate MST were found 
in our research. We believe that this was caused by 
the smooth switch of regimens. It is difﬁ  cult to 
switch from one type of chemotherapy to another 
regimen if there is no obvious PD, but even in cases 
of peritoneal dissemination in which PD is difﬁ  cult 
to determine, we switched regimens with increased 
tumor markers and palpation of the Douglas cavity. 
Therefore, we were able to switch to the next 
regimen without any hesitation, because the next 
regimen had already been determined.
In addition, as shown in Figure 3, it was con-
cluded that resection of a primary tumor can further 
improve outcomes, even when it is not a curative 
resection. However, no reports clearly indicating 
this have been found.
In conclusion, this report is of the results from 
the ﬁ  rst-line chemotherapy with S-1 alone, second-
line with S-1 plus cisplatin, and third-line ﬁ  xed with 
weekly paclitaxel. In this therapy, direct curative 
effects for tumors were not high, but good survival 
rates were seen, and the side-effects were minor.
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